Institutional Equity Research for Undercovered Public Companies
Alliance Equity Research publishes independent and company-sponsored research on undercovered, emerging, and high-potential public companies globally.
Search AER-covered companies and Insights, or explore listed companies across global markets.
Latest Research
Recent initiation reports, research updates and company commentary from Alliance Equity Research.
Helus Pharma Inc.
HELP
Phase 3 Depression Programme APPROACHes a Defining Clinical Readout as Its Proprietary Serotonergic Pipeline Targets Lasting Treatment Benefits in Depression and Anxiety
An in-depth analysis of Helus Pharma’s HLP003 and HLP004 programs, assessing clinical progress, competitive positioning, commercial potential, financing needs, and risk-adjusted valuation.
ASML Holding N.V.
ASML
A Near-Monopoly Lithography Franchise Powering Global Semiconductor Supply Chain with EUV Dominance and High-NA Optionality
Initiation coverage examining EUV leadership, High-NA optionality, DUV economics, installed-base services, competitive moat, semiconductor demand drivers, valuation summary, and key risks.
Dexcom, Inc.
DXCM
Dominant CGM Franchise Leveraging Technology, Coverage Expansion, and Consumer Tailwinds to Sustain Multi-Year Growth
Initiation coverage examining CGM market leadership, product strategy, reimbursement expansion, recurring sensor economics, international growth, valuation summary, and key risks.
Insights
Timely analysis of company developments, industry trends, capital markets activity, and emerging investment themes across global public markets.
Mining & Critical MineralsMeridian’s Cabaçal Financing Offers Advance a Mine With Important Terms Unsettled
Meridian Mining has appointed an engineering and construction management contractor for its Cabaçal copper-gold project in Brazil and received indicative financing proposals, including packages totaling $400 million. The project’s feasibility study models a $2.09 billion after-tax net present value, but its initial capital estimate relies on tax credits and excludes financing charges. The financing offers remain subject to negotiation, while the mine installation permit was under review in the October technical report. The crucial issue for investors is how much of the modeled project value Meridian can retain after construction funding, sales arrangements and other obligations are settled.
EnergyCentrus’s $7 Billion Backlog Depends on Building Its Uranium Enrichment Capacity
Centrus Energy has started shipping centrifuges for a proposed expansion of U.S. uranium-enrichment capacity. Its $7.0 billion backlog signals substantial potential demand, but includes $5.4 billion of contingent sales commitments and government contract options that may not be exercised. Quarterly net income also benefited from a noncash warrant gain. A strong cash balance gives Centrus resources to advance construction, while milestone payments, financing terms and the cost of bringing capacity online will determine how much of the opportunity reaches shareholders.
Biotechnology & HealthcareRigel’s VEPPANU Launch Adds Growth, With Royalties and Costs Still to Absorb
Rigel Pharmaceuticals has begun selling VEPPANU, an oral treatment for a defined group of patients with advanced breast cancer. The drug generated $6.6 million in net sales in its first partial quarter, providing most of Rigel’s year-over-year product sales growth in the third quarter. The company’s 2026 revenue guidance excludes the new medicine, making the established portfolio’s performance and launch sales separate measures. Royalties, development commitments and commercialization costs will determine how much of VEPPANU’s revenue Rigel retains as profit.
Industrials & AerospaceAdvanSix’s Rising Sales Mask Weaker Earnings as Ammonia Expansion Advances
AdvanSix reported higher third-quarter sales as it passed through rising raw-material costs, but lower production and input inflation reduced earnings. The U.S. manufacturer supplies nylon materials, fertilizers and industrial chemicals through an integrated network. Quarterly cash flow improved with help from working-capital movements, while free cash flow remained negative for the first nine months. A proposed federal grant could support a multiyear ammonia expansion. The company’s near-term cash position depends on customer advances, spending and operating performance, while the expansion remains subject to federal review.
Technology & SemiconductorsNova’s Chip Measurement Sales Rise as Memory and Packaging Investment Expands
Nova reported a 28% increase in third-quarter revenue as semiconductor manufacturers bought more of its measurement equipment. The company helps chipmakers inspect the dimensions and materials of devices during production and has expanded its presence in advanced packaging. Higher gross profit outpaced the increase in operating expenses, lifting operating margin. Nova expects further sequential revenue growth in the fourth quarter, although future demand will depend on how customers divide their spending among memory, logic and packaging projects. The results also show how working-capital movements can affect cash generation from one quarter to the next.
Biotechnology & HealthcareBioCryst’s Revenue Outlook Rises as Pharmacy Inventory Complicates ORLADEYO Sales Growth
BioCryst raised its 2026 total revenue outlook after reporting third-quarter growth in ORLADEYO, its medicine for preventing hereditary angioedema attacks. The company left its product-specific forecast unchanged and said the broader increase reflects licensing revenue and orders for another medicine. A new pharmacy’s initial inventory also contributed to the quarter’s sales. Against that backdrop, BioCryst is funding a late-stage study of navenibart while meeting debt and royalty obligations. The results call for a closer look at recurring patient demand, cash commitments and the company’s next clinical milestone.
Technology & SemiconductorsAdvanced Energy’s Chip and Data-Center Growth Brings Higher Profits and Greater Cash Needs
Advanced Energy’s third-quarter sales rose 50% as demand increased for power equipment used in semiconductor manufacturing and data centers. Higher volumes and margins lifted operating profit, but the company also committed more cash to inventory and factory expansion. Its new Thailand facility has begun serving data-center customers, and management expects continued capital spending as it expands capacity. The results highlight both the earnings potential of supplying the technology buildout and the importance of converting rising shipments into cash as new products and production lines ramp.
Technology & SemiconductorsAI’s Memory Boom Is Lifting Chipmaker Profits and Raising Costs for Device Makers
The AI infrastructure buildout is changing the economics of the memory industry. Chipmakers are allocating capacity to high-value server products and securing longer-term customer commitments, while phone and computer manufacturers face higher component costs. IDC estimates that global smartphone shipments fell 22% in the third quarter, with memory shortages contributing to the downturn. The effects are uneven: earlier inventory purchases have helped some device makers, while others face margin pressure. New factories could eventually expand supply, but their timing, product mix and returns will shape the next stage of the cycle.
Explore Coverage
AER-covered companies combine public-company information with our proprietary research, updates, and commentary.
Find AER-Covered Companies
Explore AER-covered companies by sector, region, and market capitalization.
Research Built Around the Model
Alliance Equity Research develops written company analysis and detailed financial models together. The model is used to test operating assumptions, financial outcomes, scenarios, and valuation frameworks.
- Fundamental company analysis
- Integrated financial modeling
- Scenario-based valuation framework
- Ongoing coverage after initiation
Operating Drivers
RevenuePricingVolumeKPIsFinancial Forecast
Illustrative forecast structure, without financial values Metric FY1 FY2 FY3 FY4 Revenue Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder EBITDA Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder FCF Forecast output placeholder Forecast output placeholder Forecast output placeholder Forecast output placeholder Scenarios & Sensitivities
BaseUpsideDownsideValuation
DCF · Trading Multiples
Published Research
Is Your Company Undercovered?
Alliance Equity Research works with listed companies, recently listed companies, and businesses preparing to list, with a focus on undercovered, emerging, and high-potential opportunities. Our coverage includes initiation research, detailed financial modeling, and ongoing research updates.
- Initiation Research
- Financial Model
- Ongoing Updates
Investor Discovery
- AER Website
- FactSet
- LSEG Refinitiv
- AlphaSense
- Distribution Partners
Stay Current with AER
Choose the research and Insights updates you want to receive.